Search Medical Condition
Please enter condition
Please choose location

Slingerlands, New York Clinical Trials

A listing of Slingerlands, New York clinical trials actively recruiting patient volunteers.

RESULTS

Found (220) clinical trials

Efficacy and Safety of Bimatoprost Sustained-Release (SR) in Patients With Open-angle Glaucoma or Ocular Hypertension

This study will evaluate the efficacy and safety of bimatoprost sustained-release (SR) in patients with open-angle glaucoma or ocular hypertension. The study includes a 12-month treatment period with an 8-month extended follow-up.

Phase

0.0 miles

Learn More »

Safety and Efficacy of KPI-12 in Subjects With Dry Eye Disease

This is a Phase 3, multi-center, double-masked, randomized, vehicle-controlled, parallel-group study designed to evaluate the safety and efficacy of KPI-121 0.25% ophthalmic suspension versus vehicle in subjects with dry eye disease.

Phase

0.0 miles

Learn More »

InnFocus MicroShunt Versus Trabeculectomy Study

This clinical trial is a prospective, randomized, controlled, multicenter, study. After informed consent is obtained, patients will be evaluated for eligibility based on glaucoma severity, eye health, and visual acuity. Clinical follow up will be scheduled over the course of the 24 month study, and examinations will be repeated to ...

Phase

0.0 miles

Learn More »

Lacripep in Subjects With Dry Eye Associated With Primary Sj gren's Syndrome

This is a multi-center, randomized, placebo-controlled, double-masked, parallel-group study. Subjects will be randomized into three treatment groups: 0.005%, or 0.01% Lacripep, or placebo in a 1:1:1 ratio.

Phase

0.0 miles

Learn More »

Skin Incisions and Wound Complication Rates for C-sections in Obese Women

It is the purpose of this study to evaluate the relationship between a low transverse, vertical midline, and supra-panicular high transverse skin incisions and the rate of wound complications in women with a BMI of 40 or greater undergoing a cesarean section for delivery. So far, the choice of incision ...

Phase N/A

2.84 miles

Learn More »

A Study of Ixekizumab (LY2439821) in bDMARD-Naive Participants With Radiographic Axial Spondyloarthritis

The main purpose of this study is to evaluate the safety and efficacy of the study drug known as ixekizumab in biological disease-modifying anti-rheumatic drugs (bDMARDs)-naive participants with radiographic axial spondyloarthritis (rad-axSpA).

Phase

3.65 miles

Learn More »

A Study of Ixekizumab (LY2439821) in TNF Inhibitor Experienced Participants With Radiographic Axial Spondyloarthritis

The main purpose of this study is to evaluate the efficacy and safety of ixekizumab in tumor necrosis factor (TNF) inhibitor-experienced participants with radiographic axial spondyloarthritis (rad-axSpA).

Phase

3.65 miles

Learn More »

Safety Follow-up Study in Subjects With Silicone Gel-filled Breast Implants as Compared Both to Saline-filled Breast Implants and to National Norms

Ten year safety study examining rates of rare adverse events, child bearing issues, effects of mammography, MRI compliance and results, and long-term benefit of silicone-filled breast implants.

Phase N/A

3.65 miles

Learn More »

Evaluation of the Long Term Safety Tolerability and Efficacy of Two Dosing Regimens of Olokizumab (OKZ) in Subjects With Rheumatoid Arthritis (RA) Who Previously Completed 24 Weeks of Blinded Treatment in One of the Core Studies - CREDO 1 2 or 3.

The goal of this Phase III study is to evaluate the long-term safety, tolerability, and efficacy of OKZ in subjects with moderately to severely active RA who previously completed 24 weeks of double-blind treatment with OKZ in the core studies. OKZ is expected to reduce the disease activity and induce ...

Phase

3.65 miles

Learn More »

A Long Term Extension Study of Ixekizumab (LY2439821) in Participants With Axial Spondyloarthritis

The purpose of this study is to evaluate, in participants having achieved a state of sustained remission, if the ixekizumab treatment groups are superior to the placebo group in maintaining response during the randomized withdrawal-retreatment period in participants with axial spondyloarthritis.

Phase

3.65 miles

Learn More »